Who is behind ARGEA

ARGEA develops and produces the enzyme Argeon in its own biotech laboratory and brings each patient together with a treating physician who fits the case. Treatment takes place at licensed clinics in Hong Kong, the United Arab Emirates and Georgia. More than 100 patients have been treated with Argeon so far.

Director

Martin Wyss, PhD

Leads the programme. Responsible for the laboratory programme behind Argeon, patient coordination, the standards on this site and the written disclosure every patient receives. Your point of contact throughout.

contact@argea.health

Treating physicians

Selected for each patient

ARGEA does not employ a fixed medical team. For each patient we select a physician according to tumour type, language and location; a leukaemia patient and a patient with pancreatic cancer are not seen by the same specialist. All of them are licensed, trained in oncology or internal medicine, and experienced with Argeon. They review eligibility, lead the consultation, administer the therapy and sign every review. You receive their name, qualifications and licence number in writing before you consent.

Patient coordination

Care team

Nursing and coordination staff at the partner clinic handle your visits, your results and your questions between visits. You get one contact number that is answered by a person who knows your case.

WYSS PERFORMANCE LLC-FZ

ARGEA is a programme of WYSS PERFORMANCE LLC-FZ, a free-zone company registered in Dubai, United Arab Emirates. The company coordinates the programme, holds the contracts with patients and partners, and is responsible for this website.

RoleDevelopment and production of Argeon in the company's biotech laboratory, coordination, contracting, patient communication, record keeping. The company does not itself provide medical treatment; treatment is given by licensed physicians at partner clinics.

ContractsEach patient signs a treatment agreement and an informed-consent form. Both are written in plain English and reviewed with you before signing.

DataMedical records are stored encrypted, shared only with the physicians treating you and with your own oncologist, and never used for marketing. Nothing is published without your written permission.

Laboratory, clinics, diagnostics

Our laboratoryArgeon is developed and produced in our own biotech laboratory, which works on amino-acid depletion enzymes, stem-cell growth factors and extracellular vesicles. The laboratory supplies the enzyme, its preclinical data and the documentation behind every patient observation on this site. Laboratory documentation is available to clinicians on request.

Partner clinicsLicensed medical facilities in Georgia, the United Arab Emirates and Hong Kong, with oncology and internal medicine staff, laboratory access and imaging, where the therapy is administered under physician supervision. Named to each patient in writing after the eligibility review.

DiagnosticsASS1 and OTC immunohistochemistry on existing tumour tissue, arginine measurement, tumour markers, circulating tumour cell analysis and liver elastography where indicated, through accredited laboratories.

How we work

Straight answersWhat is known and what is not, in writing, before you pay anything.

We stand behind itFor tumours confirmed suitable, we guarantee no further growth during treatment, or your money back. The terms depend on your case and are fixed in writing in your treatment agreement before you pay anything.

Your oncologist stays in chargeWe add to a treatment plan; we do not replace it. We do not treat against a considered medical opinion without a second one.

Stop when it is not workingReviews at weeks 8, 16 and 24 exist to end treatment that is not helping. You pay for blocks started, never for the full course up front.

Full recordsEvery value measured goes to you and your oncologist. The programme keeps complete records so that what we learn from each patient is not lost.

Ask us whether your tumour is a candidate

Request eligibility review